Questionnaire

This questionnaire saves your responses automatically every 20 seconds if you are interrupted while answering.

1. Medications belonging to the csDMARD class include:

2. The mechanism of action of infliximab is inhibition of:

3. Usually, csDMARDs are prescribed after the failure of first-line b/tsDMARD treatment.

4. Choice of b/tsDMARD therapy is dependent on:

5. Special consideration is necessary when selecting a b/tsDMARD for patients with rheumatoid disorders and comorbid:

6. Upon initiation of treatment for latent TB, b/tsDMARD therapy should be:

7. Vaccination with live attenuated viruses is contraindicated during b/tsDMARD therapy.

8. In the case of joint replacement surgery, b/tsDMARDs should be withheld for at least one month pre- and post-surgery. Tocilizumab should be withheld for longer as it has been associated with delayed wound healing and an increased risk of infection.

9. SARAA eligibility criteria for b/tsDMARD therapies in RA include:

10. Therapies that should be avoided in patients with RA and who have had a serious infection in the previous 12 months or are at high risk of serious infection include:

11. Tailored treatment for axSpA should be individualised according to current:

12. SARAA eligibility criteria for b/tsDMARD therapies in axSpA are:

13. SARAA-recommended second-line therapy for axSpA patients with purely axial disease is:

14. SARAA recommendations for management of PsA include:

15. SARAA eligibility criteria for b/tsDMARD therapies in PsA include: